Skip to content

Study · Observational study · n = 65 · 2013

4 results

Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide.

Casar-Borota O, Heck A, Schulz S, Nesland JM, Ramm-Pettersen J, Lekva T, Alafuzoff I, Bollerslev J

The Journal of clinical endocrinology and metabolism3 Oct 2013Cited by 107 (Europe PMC)

PMID24092823 (opens in a new tab)DOI10.1210/jc.2013-2145 (opens in a new tab)PepBankPUB-24092823
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyMechanism

    In somatotroph adenomas, SSTR2a expression was lower in octreotide-pretreated patients than untreated patients.

    In plain wordsIn patients with somatotroph adenomas, octreotide pretreatment was linked to lower SSTR2a expression than no pretreatment.

    Peptide
    Octreotide
    Outcome
    DecreaseSSTR2a expression after pretreatment
    Study

    n = 65

    Comparator
    No octreotide pretreatment
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SSTR2a expression was reduced in the pretreated group and correlated with the acute octreotide test results and the effect of octreotide treatment.
    3 context sentences
    Summary · context
    After exclusion of 13 patients, immunohistochemical analysis with rabbit monoclonal antibodies against SSTRs 1, 2a, 3, and 5 (clones UMB-7, -1, -5, and -4) was performed on 65 adenomas.
    Summary · context
    Twenty-eight patients received preoperative octreotide, and 37 patients were operated on without pretreatment.
    Summary · context
    The responses to the octreotide test dose (GH reduction) and to 6 months of octreotide (IGF-I reduction) were measured.
  2. 02HumanObservational studyMechanism

    In somatotroph adenomas, SSTR2a expression correlated with response to the acute octreotide test.

    In plain wordsIn patients with somatotroph adenomas, SSTR2a expression was linked to response to the acute octreotide test.

    Peptide
    Octreotide
    Outcome
    Direction not reportedSSTR2a association with acute test response
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SSTR2a expression was reduced in the pretreated group and correlated with the acute octreotide test results and the effect of octreotide treatment.
    3 context sentences
    Summary · context
    After exclusion of 13 patients, immunohistochemical analysis with rabbit monoclonal antibodies against SSTRs 1, 2a, 3, and 5 (clones UMB-7, -1, -5, and -4) was performed on 65 adenomas.
    Summary · context
    Twenty-eight patients received preoperative octreotide, and 37 patients were operated on without pretreatment.
    Summary · context
    The responses to the octreotide test dose (GH reduction) and to 6 months of octreotide (IGF-I reduction) were measured.
  3. 03HumanObservational studyMechanism

    In somatotroph adenomas, SSTR2a expression correlated with the effect of octreotide treatment.

    In plain wordsIn patients with somatotroph adenomas, SSTR2a expression was linked to the octreotide treatment response.

    Peptide
    Octreotide
    Outcome
    Direction not reportedSSTR2a association with treatment effect
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    SSTR2a expression was reduced in the pretreated group and correlated with the acute octreotide test results and the effect of octreotide treatment.
    3 context sentences
    Summary · context
    After exclusion of 13 patients, immunohistochemical analysis with rabbit monoclonal antibodies against SSTRs 1, 2a, 3, and 5 (clones UMB-7, -1, -5, and -4) was performed on 65 adenomas.
    Summary · context
    Twenty-eight patients received preoperative octreotide, and 37 patients were operated on without pretreatment.
    Summary · context
    The responses to the octreotide test dose (GH reduction) and to 6 months of octreotide (IGF-I reduction) were measured.
  4. 04HumanObservational studyMechanism

    In somatotroph adenomas, adjustment for medical pretreatment improved the correlation between SSTR2a expression and acute octreotide test response.

    In plain wordsIn patients with somatotroph adenomas, adjusting for pretreatment strengthened the link between SSTR2a expression and acute octreotide response.

    Peptide
    Octreotide
    Outcome
    Direction not reportedAdjusted acute-response correlation
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In a linear regression model with SSTR2a expression as the determinant, the correlation with the acute test response improved after adjustment for medical pretreatment.
    3 context sentences
    Summary · context
    After exclusion of 13 patients, immunohistochemical analysis with rabbit monoclonal antibodies against SSTRs 1, 2a, 3, and 5 (clones UMB-7, -1, -5, and -4) was performed on 65 adenomas.
    Summary · context
    Twenty-eight patients received preoperative octreotide, and 37 patients were operated on without pretreatment.
    Summary · context
    The responses to the octreotide test dose (GH reduction) and to 6 months of octreotide (IGF-I reduction) were measured.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.